



**Supplemental Figure 1. Kaplan-Meier plot, illustrating the impact of the sorafenib-induced decrease in the number of ERK+EPC on overall survival of HCC patients(n=9). The patient set was bifurcated at the median of the observed post-pre differences. The Log-rank test was used to compare survival in patients classified as Greater decline, to those with Lesser decline.**